Fish oil emulsions in the management of intestinal failure-associated liver disease

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The role of parenteral lipid emulsions in the treatment of intestinal failure-associated liver disease (IFALD) is both topical and controversial. There is strong evidence supporting plant-based (soy, olive) lipid emulsions as a key cause for IFALD, especially in neonates. As a result, alternate lipid formulations, most notably fish oil emulsions (FOE) have come into widespread use despite somewhat limited clinical data on their overall benefit and potential long-term consequences. This review examines putative mechanisms of action of FOE in reversing cholestasis associated with IFALD, and critically reviews published clinical studies of the use of FOE in pediatric patients with IFALD. From these works, it appears the mechanism of action of FOE is most likely related to the reduction of serum phytosterols associated with plant-based lipid emulsions rather than a specific positive benefit of the fish oils themselves. Although the use of FOE seems to correlate with a reduction in cholestasis, their actual individual benefit is not established, and data on long-term outcomes and safety are not yet available.

Original languageEnglish (US)
Pages (from-to)823-827
Number of pages5
JournalJournal of Clinical Gastroenterology
Volume46
Issue number10
DOIs
StatePublished - Nov 1 2012

Fingerprint

Fish Oils
Emulsions
Liver Diseases
Lipids
Cholestasis
Phytosterols
Olea
Treatment Failure
Newborn Infant
Pediatrics
Safety
Serum

Keywords

  • IFALD
  • PNALD
  • cholestasis
  • fish oil
  • intestinal failure
  • intestinal failure-associated liver disease
  • parenteral nutrition-associated liver disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fish oil emulsions in the management of intestinal failure-associated liver disease. / Mercer, David F.

In: Journal of Clinical Gastroenterology, Vol. 46, No. 10, 01.11.2012, p. 823-827.

Research output: Contribution to journalReview article

@article{b681f8ab83514ad88bc1193e5db8edd6,
title = "Fish oil emulsions in the management of intestinal failure-associated liver disease",
abstract = "The role of parenteral lipid emulsions in the treatment of intestinal failure-associated liver disease (IFALD) is both topical and controversial. There is strong evidence supporting plant-based (soy, olive) lipid emulsions as a key cause for IFALD, especially in neonates. As a result, alternate lipid formulations, most notably fish oil emulsions (FOE) have come into widespread use despite somewhat limited clinical data on their overall benefit and potential long-term consequences. This review examines putative mechanisms of action of FOE in reversing cholestasis associated with IFALD, and critically reviews published clinical studies of the use of FOE in pediatric patients with IFALD. From these works, it appears the mechanism of action of FOE is most likely related to the reduction of serum phytosterols associated with plant-based lipid emulsions rather than a specific positive benefit of the fish oils themselves. Although the use of FOE seems to correlate with a reduction in cholestasis, their actual individual benefit is not established, and data on long-term outcomes and safety are not yet available.",
keywords = "IFALD, PNALD, cholestasis, fish oil, intestinal failure, intestinal failure-associated liver disease, parenteral nutrition-associated liver disease",
author = "Mercer, {David F}",
year = "2012",
month = "11",
day = "1",
doi = "10.1097/MCG.0b013e318261836d",
language = "English (US)",
volume = "46",
pages = "823--827",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Fish oil emulsions in the management of intestinal failure-associated liver disease

AU - Mercer, David F

PY - 2012/11/1

Y1 - 2012/11/1

N2 - The role of parenteral lipid emulsions in the treatment of intestinal failure-associated liver disease (IFALD) is both topical and controversial. There is strong evidence supporting plant-based (soy, olive) lipid emulsions as a key cause for IFALD, especially in neonates. As a result, alternate lipid formulations, most notably fish oil emulsions (FOE) have come into widespread use despite somewhat limited clinical data on their overall benefit and potential long-term consequences. This review examines putative mechanisms of action of FOE in reversing cholestasis associated with IFALD, and critically reviews published clinical studies of the use of FOE in pediatric patients with IFALD. From these works, it appears the mechanism of action of FOE is most likely related to the reduction of serum phytosterols associated with plant-based lipid emulsions rather than a specific positive benefit of the fish oils themselves. Although the use of FOE seems to correlate with a reduction in cholestasis, their actual individual benefit is not established, and data on long-term outcomes and safety are not yet available.

AB - The role of parenteral lipid emulsions in the treatment of intestinal failure-associated liver disease (IFALD) is both topical and controversial. There is strong evidence supporting plant-based (soy, olive) lipid emulsions as a key cause for IFALD, especially in neonates. As a result, alternate lipid formulations, most notably fish oil emulsions (FOE) have come into widespread use despite somewhat limited clinical data on their overall benefit and potential long-term consequences. This review examines putative mechanisms of action of FOE in reversing cholestasis associated with IFALD, and critically reviews published clinical studies of the use of FOE in pediatric patients with IFALD. From these works, it appears the mechanism of action of FOE is most likely related to the reduction of serum phytosterols associated with plant-based lipid emulsions rather than a specific positive benefit of the fish oils themselves. Although the use of FOE seems to correlate with a reduction in cholestasis, their actual individual benefit is not established, and data on long-term outcomes and safety are not yet available.

KW - IFALD

KW - PNALD

KW - cholestasis

KW - fish oil

KW - intestinal failure

KW - intestinal failure-associated liver disease

KW - parenteral nutrition-associated liver disease

UR - http://www.scopus.com/inward/record.url?scp=84867736058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867736058&partnerID=8YFLogxK

U2 - 10.1097/MCG.0b013e318261836d

DO - 10.1097/MCG.0b013e318261836d

M3 - Review article

C2 - 23060217

AN - SCOPUS:84867736058

VL - 46

SP - 823

EP - 827

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 10

ER -